Abstract Search

ba0003oc6.4 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

Ferrari S , Adachi JD , Lippuner K , Zapalowski C , Miller PD , Reginster J-Y , Torring O , Kendler DL , Daizadeh N , Wang A , O'Malley CD , Wagman RB , Libanati C , Lewiecki EM

Objective: Evidence for further reduction of nonvertebral fracture (NVFX) beyond 3 years of antiresorptive therapy is limited. Since long-term denosumab (DMAb) treatment is associated with continuous increases in BMD and sustained fracture reduction, we analyzed the influence of femoral neck (FN) BMD after 3 years on NVFX rates.Methods: Long-term subjects received 7 continuous years of DMAb; cross-over subjects received 3 years of placebo (FREEDOM) and 4...

0 shares

Bone Abstracts

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

BiosciAbstracts